DiaMedica Therapeutics (DMAC) Research & Development (2018 - 2026)

DiaMedica Therapeutics has reported Research & Development for 9 years, with the latest figure at $8.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 41.21% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $26.9 million (up 28.08% YoY), and the FY2025 full-year result was $24.6 million, up 29.16% from the prior year.
• Research & Development for Q1 2026 stood at $8.0 million, up from $6.7 million in the prior quarter.
• The five-year high for Research & Development was $8.0 million in Q1 2026, with the low at $1.6 million in Q3 2022.
• Historically, Research & Development has averaged $4.3 million across 5 years, with a median of $3.7 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development slipped 29.67% — and 2023, when it soared 99.51%.
• DiaMedica Therapeutics' Research & Development stood at $2.3 million in 2022, then surged by 61.98% to $3.7 million in 2023, then soared by 75.96% to $6.5 million in 2024, then advanced by 3.54% to $6.7 million in 2025, then advanced by 19.23% to $8.0 million in 2026.
• The last three Research & Development figures came in at $8.0 million (Q1 2026), $6.7 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.